Azithromycin, a macrolide, is one of the most commonly prescribed antibiotics in the US, with an estimated 44.9 million prescriptions dispensed to outpatients in 2016.
1 A safety concern was raised following a study by Ray et al in 2012
2 that reported an association of azithromycin use with sudden cardiac death. Prompted by concern over QT prolongation and reports of cardiac deaths, the US Food and Drug Administration made changes to the product labeling between 2011 and 2013 advising against using azithromycin in patients with known risk factors for ventricular arrhythmia.
3